Healthy adults ( aged 18-60 years ) were sequentially enrolled and randomly assigned ( 2:1 ) , by computer-generated block randomisation ( block size of six ) , to receive placebo , low-dose adenovirus type-5 vector-based Ebola vaccine , or high-dose vaccine .